Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Sanara MedTech is a specialty wound care and skincare company focused on chronic wound management products, primarily serving the advanced wound care market through distribution to hospitals, wound care centers, and long-term care facilities. The company markets products including CellerateRX surgical activated collagen, BIAKŌS antimicrobial skin and wound cleanser, and HYCOL hydrolyzed collagen, competing in the $15+ billion US advanced wound care market. Despite 33% revenue growth, the company remains unprofitable with negative operating cash flow and elevated leverage (7.7x D/E), reflecting heavy investment in commercial expansion and working capital.
Sanara operates a specialty pharmaceutical distribution model, sourcing advanced wound care formulations and marketing them through a direct sales force to hospitals, wound care centers, skilled nursing facilities, and home health agencies. The 90.6% gross margin reflects the high-value nature of specialty wound care products with limited direct competition and clinical differentiation. Revenue growth is driven by expanding the commercial sales team, penetrating new accounts in the fragmented post-acute care market, and cross-selling multiple products within existing customer relationships. The company does not manufacture products but controls formulations and branding, capturing margin through specialized distribution and clinical education rather than manufacturing scale.
Quarterly revenue growth rates and guidance - market expects sustained 25-35% growth to justify valuation
Path to profitability metrics - operating margin trajectory and timeline to positive EBITDA
New product launches and FDA clearances for wound care formulations
Major hospital system or GPO (group purchasing organization) contract wins
Sales force productivity metrics - revenue per rep and account penetration rates
Working capital management and cash burn rate given negative operating cash flow
Medicare/Medicaid reimbursement rate changes for wound care products and services - CMS policy shifts could compress end-market demand or pricing power
Regulatory pathway changes for wound care products (FDA reclassification from 510(k) to PMA could increase barriers but also competition)
Shift toward value-based care and bundled payments may pressure wound care product pricing as hospitals seek lower-cost alternatives
Technological disruption from advanced biologics, growth factors, or cellular therapies that could render collagen-based products less competitive
Large medical device incumbents (Smith & Nephew, Mölnlycke, 3M, ConvaTec) have significantly greater resources for R&D, clinical studies, and sales force scale
Private label and generic wound care products from distributors (Cardinal Health, McKesson) could erode pricing in cost-sensitive segments
Limited product differentiation in commodity wound care categories - clinical evidence and outcomes data critical to maintain premium positioning
High leverage (7.7x D/E) combined with negative cash flow creates refinancing risk and limits financial flexibility for acquisitions or product development
Negative $10M operating cash flow and minimal cash generation requires external financing - equity dilution risk if capital markets tighten
Working capital intensity (inventory for specialty products, 60-90 day receivables) consumes cash during growth phase
Covenant compliance risk if revenue growth slows or losses widen - debt agreements likely contain EBITDA or liquidity covenants
low-to-moderate - Chronic wound care is relatively non-discretionary as it addresses medical necessity (diabetic ulcers, surgical wounds, pressure injuries). However, elective surgical volumes can decline in recessions, affecting surgical wound care product demand. The post-acute care market (skilled nursing, home health) is more resilient than acute care but faces reimbursement pressure. Medicare and Medicaid funding (70%+ of wound care reimbursement) provides stability, though budget constraints can impact facility purchasing decisions.
Rising interest rates create multiple headwinds: (1) Higher cost of debt service on the 7.7x D/E balance sheet, directly impacting cash flow; (2) Valuation multiple compression for unprofitable growth companies as investors demand higher risk premiums; (3) Potential tightening of credit availability for additional financing if needed to fund operations. The company's negative cash flow makes it vulnerable to financing market conditions. Lower rates would ease refinancing risk and support growth stock valuations.
High exposure to credit conditions given negative operating cash flow, elevated leverage, and potential need for additional capital to reach profitability. Tightening credit markets could limit access to growth capital or force dilutive equity raises. Customer credit risk is moderate - hospitals and skilled nursing facilities have payment cycles of 60-90 days, and any deterioration in their financial health (often tied to reimbursement rates and occupancy) could extend DSO or increase bad debt.
growth - The stock appeals to small-cap growth investors willing to accept near-term losses and high volatility for exposure to the expanding chronic wound care market. The 33% revenue growth, 90% gross margins, and large addressable market attract momentum investors, while the negative cash flow and 7.7x leverage deter value and income investors. Institutional ownership is likely limited given the $200M market cap and unprofitability. The -44% one-year return reflects de-rating of unprofitable healthcare growth stocks as interest rates rose in 2024-2025.
high - Small-cap unprofitable healthcare companies exhibit elevated volatility (typical beta 1.5-2.0x) due to binary outcomes around product launches, regulatory decisions, and quarterly earnings beats/misses. The -37.7% six-month decline demonstrates sensitivity to growth stock sentiment and financing concerns. Low float and limited institutional ownership amplify price swings on modest volume.